Biogen (BIIB) PT Lowered to $139 at BMO Capital; 'No Easy Answers to Get Back to Growth'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Biogen (NASDAQ: BIIB) to $139.00 (from $156.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
